Screener
ARS Pharmaceuticals, Inc. SPRY Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -185%— | -204.5%— | -212.9%— | —— | —— | |
| Net margin | -184.2%-142pp | -200%-184pp | -203.3%-212pp | -56.1%+1,856pp | -42.7%+8,926pp | |
| Returns | ||||||
| Return on equity | -210.3%-187pp | -136.4%-129pp | -92.3%-95.6pp | -45.9%-23.5pp | -23.6%-4.2pp | |
| Return on invested capital | -177.7%-113pp | -125.5%-85.0pp | -95.6%-70.2pp | -78.3%-42.5pp | -65%-28.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.3×0.0× | 0.2×-0.1× | 0.5×+0.5× | 0.4×+0.4× | |
| Liquidity | ||||||
| Current ratio | 3.5×-2.7× | 4.9×-6.1× | 7.3×-7.0× | 6.7×-5.9× | 6.2×-26.7× | |
| Leverage | ||||||
| Debt-to-equity | 7.7×+7.7× | 1.6×+1.6× | 0.8×+0.8× | 0.7×+0.7× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $0.13-93.6% | $0.62-73.6% | $1.16-53.8% | $1.49-27.8% | $1.96-12.0% | |
| Valuation | ||||||
| Market capitalization | $409.72M-59.7% | $797.36M-35.4% | $1.15B+12.3% | $993.2M-29.3% | $1.65B+101% | |
| Price / sales | 3.5×-3.6× | 8.1×-4.7× | 13.7×+2.2× | 7×-540× | 14.7×-1,628× | |
| Price / book | 32.7×+25.9× | 13×+7.6× | 10.1×+6.1× | 6.7×-0.3× | 8.6×+4.8× |
FAQ
- Where do ARS Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from ARS Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
